ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2087

Prevalence of Corticosteroid Use in Incidental Vertebral or Hip Fractures

Gurjit Kaeley 1, Julie Ferm 2 and Lanh Dang2, 1University of Florida, Gainesville, FL, 2UF Health Jacksonville, Jacksonville, FL

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: corticosteroids and fractures, Fracture risk

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 12, 2019

Title: Epidemiology & Public Health Poster III: OA, Gout, & Other Diseases – ARP

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Non-traumatic vertebral and hip fractures are detrimental complications of osteoporosis and those with a previous fracture have double the risk of subsequent fractures. The objective of this quality improvement (QI) project was to determine the baseline characteristics that may have contributed to the vertebral or hip fracture and determine if bone health was optimized subsequent to the fracture. As corticosteroids can increase the risk of osteoporotic fractures, the initial focus of this analysis was on patients who had an outpatient prednisone prescription prior to admission.

Methods: Data was retrospectively collected from the electronic health record for patients aged 45 and older admitted to UF Health Jacksonville for an active vertebral or hip fracture diagnosis between January 1, 2017 and January 31, 2019. Traumatic injuries were excluded. Retrospective chart review could occur dating back to January 2014 for completeness. Data on patient demographics, any medication that may affect bone health (e.g. steroids, calcium and vitamin D products, bisphosphonates, etc.), DEXA scans, and pertinent labs were collected.

Results: A total of 287 patients were admitted 296 times between January 1, 2017 and January 31, 2019. Of these, 24 patients (8.4%) had an outpatient order for prednisone on at least one occasion prior to admission. Over half of the patients, 58.3%, had an outpatient order for prednisone with an associated diagnosis of chronic obstructive pulmonary disease. A majority, 79.2%, were female with a median age of 70.5 years old (range: 57 – 98 years old). More admissions were due to hip fractures (54.2%) than vertebral fractures (45.8%). Chronic prednisone use ≥ 15 mg/day prior to admission was noted in 9.1% of patients. The remaining 22 patients had prednisone bursts with 9.1% of patients having cumulative burst doses between 10-100 mg, 68.2% patients between 101-500 mg, 18.2% patients between 501-1000 mg, and 4.5% patients > 1000 mg. Of the 24 patients, six patients had a DEXA scan prior to admission and of these DEXA scans, 2 showed osteoporosis and 3 showed osteopenia in the affected fracture area at baseline. Only 8.3% of patients were on a bisphosphonate prior to admission. Baseline Vitamin D 25-OH levels were available in 12 patients with an average level of 30.365 ± 11.35 ng/mL.

Conclusion: In this convenience sample of patients who had an outpatient order for prednisone prior to admission, more hip fractures occurred than vertebral fractures. A small percentage of patients (9%) were on prednisone chronically. The rate of baseline DEXA scan was low as only 25% of patients had one available despite approximately 68% of patients having a cumulative prednisone dose exposure between 101 – 500 mg. The rate of bisphosphate use prior to admission was also low at 8.3%. Data collection for the patients not on prednisone is ongoing. The goal of this QI project is to create a care pathway for patients admitted to the hospital for vertebral or hip fractures to optimize bone health by mitigating modifiable risk factors and increasing appropriate osteoporosis medication prescriptions to reduce the future risk of fractures. No correlation can be made at this time between prednisone use, osteoporosis, and fracture incidence.


Disclosure: G. Kaeley, None; J. Ferm, None; L. Dang, None.

To cite this abstract in AMA style:

Kaeley G, Ferm J, Dang L. Prevalence of Corticosteroid Use in Incidental Vertebral or Hip Fractures [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/prevalence-of-corticosteroid-use-in-incidental-vertebral-or-hip-fractures/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/prevalence-of-corticosteroid-use-in-incidental-vertebral-or-hip-fractures/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology